Pixantrone is a novel aza-anthracenedione that may offer clinical efficacy for relapsed or refractory diffuse large B-cell lymphoma while potentially minimizing the cardiac toxicity typically associated with anthracyclines.
May support pixantrone evaluation in relapsed/refractory DLBCL; leaves open confirmation of efficacy and cardiac safety in randomized trials.
Diffuse large B-cell lymphoma is the most common non-Hodgkin’s lymphoma. Although over 50% of patients are cured with first-line therapy that includes an anthracycline, there are a number of patients who require systemic therapy for relapsed or refractory disease. Currently, no drug is approved for this indication. Pixantrone, a novel aza-anthracenedione, was developed to maintain clinical efficacy while minimizing the cardiac toxicity associated with anthracyclines. Initial results of clinical trials demonstrate that pixantrone induces responses in this difficult-to-treat patient population with tolerable side effects. Results of ongoing clinical trials will better define pixantrone’s role in treating diffuse large B-cell lymphoma and help assess its long-term cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Beaven et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: